title: Abnormal saccadic distractibility in patients with schizophrenia: a 99mTc-HMPAO SPET study.
abstract: Recent research has shown that some patients with schizophrenia have a severe impairment in the suppression of reflexive saccadic eye movements in the ANTI-saccade task. This saccadic distractibility has previously been found in patients with lesions of dorsolateral prefrontal cortex, implicating an abnormality of prefrontal cortex. The objective of the present study was to determine the contribution of these and other areas to the ANTI-saccadic abnormality in schizophrenia by functional neuroimaging. Using 99mtechnetium-HMPAO high resolution multidetector single-photon emission tomography, regional cerebral blood flow (rCBF) during performance of the ANTI-saccade eye-movement task was compared, by statistical parametric mapping, in ten male schizophrenic patients on stable antipsychotic medication who had a high distractibility error rate on the task, and eight similar patients who had normal distractibility error rates. Compared with the normal error group, the patients with high error rates showed significantly decreased rCBF bilaterally, in the anterior cingulate, insula, and in left striatum. These same patients also had increased perseverative errors on the Wisconsin Card Sort Test.
authors.affiliation: Academic Unit of Neurosciences, Charing Cross and Westminster Medical School, London.
authors.forename: T J
authors.initials: TJ
authors.lastname: Crawford
authors.forename: B K
authors.initials: BK
authors.lastname: Puri
authors.forename: K S
authors.initials: KS
authors.lastname: Nijran
authors.forename: B
authors.initials: B
authors.lastname: Jones
authors.forename: C
authors.initials: C
authors.lastname: Kennard
authors.forename: S W
authors.initials: SW
authors.lastname: Lewis
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001143:Arousal / Q000187:drug effects / Q000502:physiology*; D001288:Attention / Q000502:physiology*; D001921:Brain / Q000098:blood supply* / Q000000981:diagnostic imaging / Q000503:physiopathology; D001931:Brain Mapping; D004292:Dominance, Cerebral / Q000502:physiology; D005625:Frontal Lobe / Q000098:blood supply / Q000000981:diagnostic imaging / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D015609:Organotechnetium Compounds; D010091:Oximes; D017397:Prefrontal Cortex / Q000098:blood supply / Q000000981:diagnostic imaging / Q000503:physiopathology; D012016:Reference Values; D012018:Reflex / Q000187:drug effects / Q000502:physiology; D012039:Regional Blood Flow / Q000187:drug effects / Q000502:physiology; D012438:Saccades / Q000187:drug effects / Q000502:physiology*; D012559:Schizophrenia / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D012565:Schizophrenic Psychology; D019690:Technetium Tc 99m Exametazime; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D014150:Antipsychotic Agents; D015609:Organotechnetium Compounds; D010091:Oximes; D019690:Technetium Tc 99m Exametazime